

## Minutes of the Meeting of the Welsh Health Specialised Services Committee

held on 10 July 2018  
at Health and Care Research, Castlebridge 4,  
Cowbridge Road East, Cardiff

### Members Present

|                      |      |  |
|----------------------|------|--|
| Vivienne Harpwood    | (VH) | Chair  |
| Carole Bell          | (CB) | Director of Nursing and Quality Assurance, WHSSC                           |
| Gary Doherty (by VC) | (GD) | Chief Executive, Betsi Cadwaladr UHB                                       |
| Charles Janczewski   | (CJ) | Independent Member/Chair of the WHSSC Quality and Patient Safety Committee |
| Sian Lewis           | (SL) | Managing Director, WHSSC   |
| Lyn Meadows (by VC)  | (LM) | Vice Chair   |
| Steve Moore          | (SM) | Chief Executive, Hywel Dda UHB   |
| Tracy Myhill         | (TM) | Chief Executive, Abertawe Bro Morgannwg UHB                                |
| Judith Paget         | (JP) | Chief Executive, Aneurin Bevan UHB   |
| Len Richards         | (LR) | Chief Executive, Cardiff and Vale UHB                                      |
| Carol Shillabeer     | (CS) | Chief Executive, Powys THB   |
| Jennifer Thomas      | (JT) | Medical Director, WHSSC  |
| Chris Turner         | (CT) | Independent Member/Audit Lead  |
| Allison Williams     | (AW) | Chief Executive, Cwm Taf UHB   |
| John Williams        | (JW) | Associate Member/Chair of the Welsh Clinical Renal Network                 |

### Apologies

|               |      |   |
|---------------|------|---|
| Stuart Davies | (SD) | Director of Finance, WHSSC                              |
| Steve Ham     | (SH) | Chief Executive, Velindre NHS Trust                     |
| Kevin Smith   | (KS) | Committee Secretary & Head of Corporate Services, WHSSC |

### In Attendance

|                 |      |  |
|-----------------|------|--|
| Andrew Champion | (AC) | Assistant Director, Evidence, Evaluation & Effectiveness |
| Ian Langfield   | (IL) | Acting Director of Planning, WHSSC                       |
| Robert Mahoney  | (RM) | Finance Manager, Cardiff and Vale UHB                    |
| Clare Nelson    | (CN) | Acting Assistant Director of Planning, WHSSC             |
| Stacey Taylor   | (ST) | Assistant Director of Finance, WHSSC                     |

### Observers:

|                   |      |                  |
|-------------------|------|------------------|
| Simon Dean        | (SD) | Welsh Government |
| Rosemary Fletcher | (RF) |                  |

### Minutes:

|                     |      |                                     |
|---------------------|------|-------------------------------------|
| Michaella Henderson | (MH) | Corporate Governance Officer, WHSSC |
|---------------------|------|-------------------------------------|

The meeting opened at 09:30

|          |  |
|----------|--|
| JC18/031 | <p><b>Welcome, Introductions and Apologies</b><br/>The Chair formally opened the meeting and welcomed members.</p> <p>Apologies were noted as above.</p>   |
| JC18/032 | <p><b>Declarations of Interest</b><br/>There were no declarations to note. The Joint Committee noted the standing declarations.</p>  |
| JC18/033 | <p><b>Accuracy of Minutes of the meeting held 15 May 2018</b><br/>The Joint Committee <b>approved</b> the minutes of the meeting held on 15 May 2018 as a true and accurate record.</p>  |
| JC18/034 | <p><b>Matters Arising</b><br/>There were no matters arising.</p> <p><b>Action Log</b><br/>The Joint Committee <b>received</b> the action log and noted the following updates:</p> <p><b>JC18003 – Integrated Commissioning Plan 2018-21: Work Plan</b><br/>IL reported that the templates that go to the Quality and Patient Safety (Q&amp;PS) Committee had been revised and a report would be produced for Q&amp;PS setting out all the milestones for both this year's and next year's Integrated Commissioning Plan (ICP).</p> <p><b>JC18004 – Integrated Performance Report</b><br/>IL reported that following consideration by the planning team, it had not been possible to move any of the tolerances in the Integrated Performance Report but that time had been allocated at the next Management Group workshop to go through each of the tolerances and discuss whether there was any scope to move any of them.</p> <p><b>JC18005 – Report from the Quality and Patient Safety Committee</b><br/>VH noted the recommendation of Maggie Berry for appointment to the Committee. CJ noted that additional Committee members were still required as the last two meetings held had been inquorate.</p> <p><b>ACTION: Members agreed to give the matter further consideration and provide VH with the names of potential new members.</b></p> |

|          |  |
|----------|--|
| JC18/035 | <p><b>Report from the Chair</b></p> <p>The Joint Committee <b>received</b> an oral report from the Chair.</p> <p>The Chair reported that the Cabinet Secretary for Health and Social Services had completed her appraisal. The Chair reported that Major Trauma and Gender Identity Services were given as areas for particular focus in the forthcoming year.</p> <p>The Chair reported that the Cabinet Secretary had mentioned during the meeting his intention to create a different voting system for Joint Committee, EASC and NWSSP to move away from a unanimous decision requirement as previous Chairs of both WHSSC and EASC had mentioned the difficulty in relation to the operation of the WHSSC and EASC Standing Order process for voting on funding contributions. Following the meeting the Cabinet Secretary wrote a letter to the Chair and she responded in a personal capacity as there was no Joint Committee meeting before a response was due to decide on a collective response. A copy of the Chair's response was circulated to Members. It was noted that the Cabinet Secretary had also written to the Health Boards and that they would be responding separately in due course. Members agreed the Chair's response was consistent with the Committee's view and that no further action was required until such time as the Cabinet Secretary's responded further.</p> <p>The Chair reported that the Cabinet Secretary had appointed her for one more year by which time a decision may have been made on the future of WHSSC, EASC and Shared Services following the Parliamentary Review.</p> <p>The Joint Committee <b>received</b> a written report providing an update on the Chair's action taken concerning the adult thoracic surgery review consultation. Members <b>ratified</b> the Chair's action.</p> |
| JC18/036 | <p><b>Report from the Managing Director</b></p> <p>The Joint Committee <b>received</b> the report from the Managing Director.</p> <p>SL drew attention to the following items within the report which the Joint Committee discussed further:</p> <ul style="list-style-type: none"> <li>• Neonatal Interim Work Stream – Members noted that ABUHB, as the provider-lead for the work stream, would submit a report to WHSSC imminently and that Management Group would consider the report as one of the key risks identified within the ICP that is expected to emerge in year.</li> <li>• Thrombectomy / Stroke Commissioning</li> </ul>   |

|          |   |
|----------|---|
|          | <ul style="list-style-type: none"> <li>• Home Parenteral Nutrition – significant cost pressure flagged. Cost of the new contract was £500k more than the original £250k allowed for in the plan. Supplier perceived to have submitted low first year quote to secure contract. WHSSC working with C&amp;V to see what can be done to provide nursing support.</li> <li>• Proton Beam Therapy</li> <li>• Inherited Bleeding Disorders</li> <li>• Sickle Cell and Thalassaemia – Members noted that this service was not currently commissioned by WHSSC and that this was a scoping exercise through the collective commissioning framework.</li> <li>• BAHA and Cochlear – Members noted a significant increase in demand in south Wales, as well as the identification of a significant number of patients with BAHA implants that were due to become obsolete in 2018 and 2019</li> <li>• Critical Care – Members noted an increase in demand for critical care within specialised services.</li> <li>• WHSSC Corporate Values – SL reported that she had launched the new WHSSC Corporate Values on 5 July 2018 and distributed a small card showing the values</li> </ul>   |
| JC18/037 | <p><b>Use of Crizotinib in the treatment of ROS1-positive advanced non-small-cell lung cancer</b></p> <p>The Joint Committee <b>received</b> the paper setting out a proposal to fund ROS1 gene fusion testing in people with advanced non-small-cell lung cancer (NSCLC).</p> <p>Members noted patients need to have the ROS1 gene mutation to be eligible to receive Crizotinib and that approximately 650 new patients per annum would be eligible for testing. Members further noted that the most definitive test for the gene was fluorescence in situ hybridisation (FISH) but that NICE were recommending that samples are tested using IHC first (which can produce a 17% false positive rate) and then samples that tested positive would be further tested with FISH.</p> <p>AC reported that while the use of Crizotinib was NICE mandated, the draft NICE guidance issued in January 2018 was negative.</p> <p>Members resolved to:</p> <ul style="list-style-type: none"> <li>• <b>Support</b> the funding for ROS1 gene fusion analysis to allow implementation of the NICE Final Appraisal Document (FAD) for the use of Crizotinib in the treatment of ROS1 positive advanced non-small cell lung cancer.</li> </ul> |

|          |  |
|----------|--|
| JC18/038 | <p><b>2018-2021 Key Risks – Cystic Fibrosis</b></p> <p>The Joint Committee <b>received</b> the paper that set out the investment requirements for the All Wales Adult Cystic Fibrosis Centre to address the immediate clinical risk and service sustainability issue, and support the ongoing development of the service.</p> <p>Members noted the 2018-21 ICP highlighted Cystic Fibrosis as a key risk that was likely to present in year and require funding due to the service being almost at full capacity, and that additional investment in staff was necessary in order to demand the predicted increase in the patient cohort over the next year.</p> <p>Members noted the Cardiff and Vale UHB business case setting out the requirements for revenue investment for:</p> <ul style="list-style-type: none"> <li>• Investment in multi-disciplinary staff;</li> <li>• Provision of a Premixed intravenous Antibiotic Service;</li> <li>• Establishment and associated costs of proposed expansion from a 7 bed to a 16 bed unit</li> </ul> <p>Members noted the proposal that a phased approach be used to meet the objectives above with Phase 1 encompassing the first two objectives and Phase 2 the third objective.</p> <p>Members discussed standards and service levels across all providers and equality of access across Wales.</p> <p>Members resolved to:</p> <ul style="list-style-type: none"> <li>• <b>Note</b> the information presented in the report and the impact of non-investment</li> <li>• <b>Approve</b> the investment in the MDT on a recurrent basis, and the part year effect of the Premixed IV Antibiotic Service for the remainder of 2018/19. The Joint Committee <b>agreed</b> that the provider would need to submit a further proposal for recurrent funding for the Premixed IV Antibiotic Service for consideration as part of the 2019-21 Integrated Commissioning Plan.</li> </ul> |
| JC18/039 | <p><b>Neuroscience Strategy Delivery Plan</b></p> <p>The Joint Committee <b>received</b> the paper that sought approval to take forward the actions specified therein to deliver the first two years of the Specialised Neurosciences Strategy in south, mid and west Wales.</p> <p>CN gave a presentation to the Committee in support of the paper.</p> <p>Members discussed:</p>   |

|          |  |
|----------|--|
|          | <ul style="list-style-type: none"> <li>• the key actions at the various stages and the possible domino effect of failing to achieve a key action in line with the proposed timetable;</li> <li>• the need to understand what the ideal service would like;</li> <li>• the need to understand demand and capacity;</li> <li>• the activities to be commissioned through the service;</li> <li>• whether it was appropriate to incentivise the movement of patients into the correct beds, if so, how and if not then what other options should be considered.</li> </ul> <p><b>ACTION: It was agreed that the WHSSC Team would lead discussions, linking in with the Chief Operating Officers, as to the appropriate use or otherwise of incentives and other options for driving change.</b></p> <p><b>ACTION: It was agreed that a further paper around the incentivisation element of the Neurosciences Strategy would be brought to a future meeting.</b></p> <p>Members resolved to:</p> <ul style="list-style-type: none"> <li>• <b>Approve</b> the delivery plan for the first two years of the Specialised Neurosciences Strategy in south, mid and west Wales</li> <li>• <b>Note</b> the work underway to develop a delivery plan for north Powys and north Wales</li> </ul> |
| JC18/040 | <p><b>Integrated Performance Report</b><br/>The Joint Committee <b>received</b> the Integrated Performance Report.</p> <p><b>ACTION: It was agreed IL would discuss tolerance levels with Management Group at their next meeting and report back to the Joint Committee on those discussions.</b></p> <p>Members resolved to:</p> <ul style="list-style-type: none"> <li>• <b>Note</b> April performance and the action undertaken to address areas of non-compliance</li> </ul>   |
| JC18/041 | <p><b>Financial Performance Report</b><br/>The Joint Committee <b>received</b> the Financial Performance Report.</p> <p>Members noted the financial position reported in Month 2 for WHSSC was an over spend to year-end of £576k with the movements being across various budget headings, improvements in Welsh contracts and deteriorations in non-Welsh contracts and IPFR.</p> <p>ST confirmed contingencies agreed today were included in year-end forecast.</p>  |

|          |   |
|----------|---|
|          | <p><b>ACTION: It was agreed there would be a more detailed discussion at the next meeting of the year-end position.</b></p> <p>Members resolved to:</p> <ul style="list-style-type: none"> <li>• <b>Note</b> the current financial position and forecast year-end position</li> </ul>   |
| JC18/042 | <p><b>Reports from the Joint Sub-Committees</b></p> <p><b>Quality and Patient Safety Committee</b><br/>The Joint Committee <b>received</b> the report.</p> <p><b>ACTION: It was agreed members would provide feedback to CS on the draft Terms of Reference and, if there were no major changes, a Chair's Action to approve them would be noted.</b></p> <p><b>ACTION: It was agreed all members would give consideration to proposing new Independent Committee members.</b></p> <p><b>IPFR</b><br/>The Joint Committee <b>received</b> the report.</p> |
| JC18/043 | <p><b>Reports from the Joint Advisory Groups</b></p> <p><b>Welsh Renal Clinical Network</b><br/>The Joint Committee <b>received</b> the report.</p>   |
| JC18/044 | <p><b>Date and Time of Next Meeting</b></p> <p>The Joint Committee noted the date of the next meeting as the 11 September 2018.</p>   |

The meeting concluded at 15:30

**Chair's Signature:** .....

**Date:** .....